YTHDC-Targeting HBV Composition for HBsAg Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis B virus (HBV) treatments, such as nucleic acid analogs, effectively reduce viral proliferation but fail to inhibit the hepatitis B surface antigen (HBsAg), hindering the elimination of infected cells by the host immune system.
Innovation Solution
A pharmaceutical composition that inhibits the expression or function of proteins belonging to the YTHDC family, particularly YTHDC1 and YTHDC2, using inhibitors like antibodies, peptides, or double-stranded RNA to reduce HBsAg production and HBV DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acid analogs are used to treat hepatitis B, then viral proliferation is reduced, but HBsAg production is not inhibited
Solution Approach 1:
The patent divides the treatment approach into two distinct mechanisms: nucleic acid analogs for inhibiting viral DNA replication and YTHDC1 inhibitors for blocking HBsAg production. This segmentation allows each component to target specific aspects of the viral lifecycle independently, resolving the contradiction where one treatment reduces proliferation but fails to inhibit antigen production.
Solution Approach 2:
The patent employs a composite therapeutic strategy combining nucleic acid analogs (such as entecavir or tenofovir) with YTHDC1 inhibitors. This composite approach integrates two different mechanisms of action into a unified treatment regimen, enabling simultaneous suppression of viral replication and HBsAg production, thereby overcoming the limitations of monotherapy.
2Reliability
If YTHDC1 is inhibited to reduce HBsAg production, then immune elimination of infected cells is enhanced, but viral DNA replication may be affected
Solution Approach 1:
The patent utilizes the dynamic regulation of YTHDC1 expression and function to selectively inhibit HBsAg production while preserving essential viral replication processes. By targeting YTHDC1's role in mRNA translation and stability rather than DNA replication directly, the treatment dynamically affects protein synthesis without completely halting the viral lifecycle, allowing immune systems to clear infected cells while maintaining controlled viral dynamics.
Data Source
AI summary
An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits the production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits the expression or the function of a protein belonging to the YTHDC family.